Bronchiectasis

The dawn of a new era?

Michelle Prickett, Grant Waterer*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Bronchiectasis is a significant chronic health problem with major morbidity, mortality, and economic costs. However, despite the large burden of disease, much of the treatment for bronchiectasis is not guided by high-quality randomized controlled data but extrapolated from studies in patients with cystic fibrosis. Thankfully, in the past few years, we have had several high-quality publications in noncystic fibrosis bronchiectasis in the areas of nebulized antibiotic therapy and chronic oral macrolide therapy. This review focuses on these recent publications as they significantly change the approach toward patients with bronchiectasis, particularly those who have frequent exacerbations.

Original languageEnglish (US)
Pages (from-to)134-137
Number of pages4
JournalClinical Pulmonary Medicine
Volume21
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bronchiectasis
Macrolides
Cystic Fibrosis
Publications
Fibrosis
Therapeutics
Economics
Anti-Bacterial Agents
Morbidity
Costs and Cost Analysis
Mortality
Health

Keywords

  • antibiotics
  • bronchiectasis
  • inhaled
  • marcolides
  • nebulized

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Prickett, Michelle ; Waterer, Grant. / Bronchiectasis : The dawn of a new era?. In: Clinical Pulmonary Medicine. 2014 ; Vol. 21, No. 3. pp. 134-137.
@article{d1bec4a7cd384ea285b0d09f4a11c1c1,
title = "Bronchiectasis: The dawn of a new era?",
abstract = "Bronchiectasis is a significant chronic health problem with major morbidity, mortality, and economic costs. However, despite the large burden of disease, much of the treatment for bronchiectasis is not guided by high-quality randomized controlled data but extrapolated from studies in patients with cystic fibrosis. Thankfully, in the past few years, we have had several high-quality publications in noncystic fibrosis bronchiectasis in the areas of nebulized antibiotic therapy and chronic oral macrolide therapy. This review focuses on these recent publications as they significantly change the approach toward patients with bronchiectasis, particularly those who have frequent exacerbations.",
keywords = "antibiotics, bronchiectasis, inhaled, marcolides, nebulized",
author = "Michelle Prickett and Grant Waterer",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/CPM.0000000000000041",
language = "English (US)",
volume = "21",
pages = "134--137",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Bronchiectasis : The dawn of a new era? / Prickett, Michelle; Waterer, Grant.

In: Clinical Pulmonary Medicine, Vol. 21, No. 3, 01.01.2014, p. 134-137.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bronchiectasis

T2 - The dawn of a new era?

AU - Prickett, Michelle

AU - Waterer, Grant

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Bronchiectasis is a significant chronic health problem with major morbidity, mortality, and economic costs. However, despite the large burden of disease, much of the treatment for bronchiectasis is not guided by high-quality randomized controlled data but extrapolated from studies in patients with cystic fibrosis. Thankfully, in the past few years, we have had several high-quality publications in noncystic fibrosis bronchiectasis in the areas of nebulized antibiotic therapy and chronic oral macrolide therapy. This review focuses on these recent publications as they significantly change the approach toward patients with bronchiectasis, particularly those who have frequent exacerbations.

AB - Bronchiectasis is a significant chronic health problem with major morbidity, mortality, and economic costs. However, despite the large burden of disease, much of the treatment for bronchiectasis is not guided by high-quality randomized controlled data but extrapolated from studies in patients with cystic fibrosis. Thankfully, in the past few years, we have had several high-quality publications in noncystic fibrosis bronchiectasis in the areas of nebulized antibiotic therapy and chronic oral macrolide therapy. This review focuses on these recent publications as they significantly change the approach toward patients with bronchiectasis, particularly those who have frequent exacerbations.

KW - antibiotics

KW - bronchiectasis

KW - inhaled

KW - marcolides

KW - nebulized

UR - http://www.scopus.com/inward/record.url?scp=84899833715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899833715&partnerID=8YFLogxK

U2 - 10.1097/CPM.0000000000000041

DO - 10.1097/CPM.0000000000000041

M3 - Review article

VL - 21

SP - 134

EP - 137

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 3

ER -